SAGE Sage Therapeutics Inc
Price (delayed)
$7.31
Market cap
$449.43M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.59
Enterprise value
$378.79M
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing
Highlights
Sage Therapeutics's EPS has increased by 27% YoY but it has decreased by 18% from the previous quarter
The net income has increased by 26% year-on-year but it has declined by 19% since the previous quarter
The company's debt has surged by 129% YoY and by 15% QoQ
The company's gross profit has shrunk by 67% QoQ and by 62% YoY
Key stats
What are the main financial stats of SAGE
Market
Valuations
Earnings
Shares outstanding
61.48M
Market cap
$449.43M
Enterprise value
$378.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
10.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.18
Revenue
$41.24M
Gross profit
$31.8M
Operating income
-$432.37M
Net income
-$400.67M
EBIT
-$400.67M
EBITDA
-$399.64M
Free cash flow
-$267.19M
Per share
Balance sheet
Liquidity
EPS
-$6.59
EPS diluted
-$6.59
Free cash flow per share
-$4.4
Book value per share
$7.6
Revenue per share
$0.68
TBVPS
$9.01
Total assets
$547.22M
Total liabilities
$82.13M
Debt
$11.84M
Equity
$465.09M
Working capital
$459.69M
Debt to equity
0.03
Current ratio
7.42
Quick ratio
7.19
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-969%
Gross margin
77.1%
Net margin
-971.5%
Operating margin
-1,048.3%
Return on assets
-60.8%
Return on equity
-68.2%
Return on invested capital
-82.7%
Return on capital employed
-84.2%
Return on sales
-971.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SAGE stock price
How has the Sage Therapeutics stock price performed over time
Intraday
2.24%
1 week
2.38%
1 month
5.33%
1 year
-67.07%
YTD
34.62%
QTD
34.62%
Financial performance
How have Sage Therapeutics's revenue and profit performed over time
Revenue
$41.24M
Gross profit
$31.8M
Operating income
-$432.37M
Net income
-$400.67M
Gross margin
77.1%
Net margin
-971.5%
Sage Therapeutics's operating margin has shrunk by 200% QoQ and by 56% YoY
The company's gross profit has shrunk by 67% QoQ and by 62% YoY
The revenue has plunged by 61% from the previous quarter and by 52% YoY
The company's net margin has shrunk by 55% YoY
Growth
What is Sage Therapeutics's growth rate over time
Valuation
What is Sage Therapeutics stock price valuation
P/E
N/A
P/B
0.96
P/S
10.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.18
Sage Therapeutics's EPS has increased by 27% YoY but it has decreased by 18% from the previous quarter
The P/B is 47% less than the 5-year quarterly average of 1.8 and 4% less than the last 4 quarters average of 1.0
SAGE's equity is down by 42% YoY and by 16% from the previous quarter
SAGE's P/S is 93% below its 5-year quarterly average of 162.3 but 38% above its last 4 quarters average of 7.8
The revenue has plunged by 61% from the previous quarter and by 52% YoY
Efficiency
How efficient is Sage Therapeutics business performance
Sage Therapeutics's ROS has plunged by 55% YoY
The ROIC has contracted by 39% from the previous quarter and by 23% YoY
Sage Therapeutics's ROE has decreased by 36% from the previous quarter and by 18% YoY
SAGE's ROA is down by 34% since the previous quarter and by 16% year-on-year
Dividends
What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SAGE.
Financial health
How did Sage Therapeutics financials performed over time
The total assets has declined by 38% year-on-year and by 12% since the previous quarter
SAGE's quick ratio is down by 29% YoY and by 26% QoQ
The company's debt is 97% lower than its equity
The debt to equity has soared by 200% YoY and by 50% from the previous quarter
The company's debt has surged by 129% YoY and by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.